Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Articles|October 28, 2024

Cell-based phenotypic screening with Incucyte® Live-Cell Analysis Systems

Author(s)Sartorius

Phenotypic screening is a vital tool in drug discovery, enabling scientists to rapidly identify potential drugs early in the discovery pipeline. Kinetic information gained by repeated image acquisition within a physiologically relevant environment provides insight into the dynamic changes which are often overlooked using end-point analysis alone.


Related to this article

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.